Clinical Trials Browser

Phase 3 × Interventional × Ramucirumab × Clear all

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05633602 2025-05-28

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06123494 2024-01-16

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Phase 3 Recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT02426125 2023-08-21

RANGE

Phase 3 Completed

530 enrolled 22 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT02435433 2023-01-20

REACH-2

Phase 3 Completed

399 enrolled 22 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02898077 2022-06-14

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Phase 3 Completed

440 enrolled 19 charts

Gastrointestinal

Gastroesophageal Junction Adenocarcinoma

NCT00703326 2021-12-06

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Phase 3 Completed

1,144 enrolled 19 charts

Breast Neoplasms

NCT02934464 2021-09-13

ARMANI

Phase 3 Unknown

Gastrointestinal

Stomach Neoplasms

NCT02314117 2021-08-26

RAINFALL

Phase 3 Completed

645 enrolled 22 charts

Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT00917384 2019-09-25

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Phase 3 Completed

355 enrolled 16 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT01168973 2019-09-25

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Phase 3 Completed

1,253 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01183780 2019-09-25

A Study in Second Line Metastatic Colorectal Cancer

Phase 3 Completed

1,072 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT01170663 2019-09-18

RAINBOW

Phase 3 Completed

665 enrolled 24 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT01140347 2015-12-28

REACH

Phase 3 Completed

565 enrolled 22 charts

Gastrointestinal

Carcinoma, Hepatocellular